| Affymax and Takeda to Present Additional Peginesatide Phase 3 Data in Dialysis ... - Business Wire (press release) |
|
|
Business Wire (press release) Peginesatide is an investigational agent in development by Affymax and Takeda for the treatment of anemia in chronic renal failure patients on dialysis. The companies and investigators will present three posters highlighting Phase 3 data on |